

Madagascar

Population 2015

24 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	12 (7.1–18)	49 (29–75)
Mortality (HIV+TB only)	1.5 (1.3–1.8)	6.3 (5.2–7.4)
Incidence (includes HIV+TB)	57 (37–82)	236 (153–337)
Incidence (HIV+TB only)	3.6 (2.2–5.4)	15 (9.1–22)
Incidence (MDR/RR-TB)**	0.46 (0.12–0.81)	1.9 (0.5–3.3)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	3.9 (1.7–6.1)	20 (9.2–31)	24 (11–37)
Males	4 (2.4–5.6)	29 (20–38)	33 (22–44)
Total	7.9 (5.1–11)	49 (37–62)	57 (37–82)

TB case notifications, 2015	
Total cases notified	29 939
Total new and relapse	29 464
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	33%
- % pulmonary	78%
- % bacteriologically confirmed among pulmonary	89%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	52% (36–80)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.25 (0.13–0.42)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	89	<1%
- on antiretroviral therapy	89	100%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			230 (17–440)
Estimated % of TB cases with MDR/RR-TB	0.49% (0–1.1)	5.9% (0–14)	
% notified tested for rifampicin resistance			569
MDR/RR-TB cases tested for resistance to second-line drugs			15
Laboratory-confirmed cases		MDR/RR-TB: 41, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 7, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New cases registered in 2014	83%	18 822
Previously treated cases registered in 2014	78%	1 949
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013	64%	14
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	26% (24–28)

TB financing, 2016	
National TB budget (US\$ millions)	9.5
Funding source: <1% domestic, 37% international, 63% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New cases
— Previously treated cases
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

